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Deciphering the signaling networks that underlie
normal and disease processes remains a major chal-
lenge. Here, we report the discovery of signaling
components involved in the Toll-like receptor (TLR)
response of immune dendritic cells (DCs), including
a previously unkown pathway shared across
mammalian antiviral responses. By combining tran-
scriptional profiling, genetic and small-molecule
perturbations, and phosphoproteomics, we uncover
35 signaling regulators, including 16 known regula-
tors, involved in TLR signaling. In particular, we find
that Polo-like kinases (Plk) 2 and 4 are essential
components of antiviral pathways in vitro and in vivo
and activate a signaling branch involving a dozen
proteins, among which is Tnfaip2, a gene associated
with autoimmune diseases but whose role was
unknown. Our study illustrates the power of
combining systematic measurements and perturba-
tions to elucidate complex signaling circuits and
discover potential therapeutic targets.
INTRODUCTION
Signaling networks detect and respond to environmental
changes, and defects in their wiring can contribute to diseases.For example, Toll-like receptors (TLRs) sense microbial mole-
cules and trigger signaling pathways critical for host defense
(Takeuchi and Akira, 2010). Genetic defects in components of
the TLR and other pathogen-sensing pathways have been linked
to human diseases. Hence, rational targeting of these pathways
should help in better manipulating immune responses associ-
ated with infections, autoimmunity, and vaccines (Hennessy
et al., 2010).
However, despite extensive studies, many components of
TLR and other biological networks are unknown, and many
genes associatedwith disease have not been assigned to a func-
tion or a pathway. A key challenge is thus to systemically dissect
mammalian signaling networks, by determining the functions of
their components and placing themwithin pathways. Previously,
we introduced an integrated experimental and computational
approach to decipher the TLR transcriptional network of immune
dendritic cells (DCs) (Amit et al., 2009), allowing us to identify
transcriptional regulators and to define their impact on TLR
responses in DCs. For example, we found a host of cell-cyle
regulators—Rbl1, Rb, Myc, Jun, and E2fs—that are required
for antiviral transcriptional responses in nondividing DCs.
Here, we adapt and expand this approach to the discovery
and validation of TLR signaling components in DCs (Figure S1
available online). First, to identify candidate components, we
rely on transcriptional feedbacks, whereby a signaling circuit
regulates the transcript levels of genes encoding some, but not
all, of its components (Amit et al., 2007; Fraser and Germain,
2009; Freeman, 2000). Second, we perturb these candidates
with shRNAs and measure the effects on a representativeCell 147, 853–867, November 11, 2011 ª2011 Elsevier Inc. 853
signature of >100 TLR-activated genes. Third, we use functional
phosphoproteomics to expand the pathway’s scope to com-
ponents whose mRNA levels may be unchanged upon TLR
activation. Applying this approach iteratively, we discovered 19
functional components, including a signaling arm mediated by
two Polo-like kinases (Plk2 and 4) that participate in regulating
well-established host antiviral pathways.
RESULTS
Transcripts for Signaling Components Are Regulated
upon TLR Stimulation
To identify candidate components of pathogen-sensing path-
ways, we used genome-wide mRNA profiles, previously mea-
sured at 10 time points along 24 hr following stimulation of
primary bone marrow-derived DCs (BMDCs) with lipopolysac-
charide (LPS; TLR4 agonist), polyinosinic:polycytidylic acid
(poly(I:C); recognized by TLR3 and the cytosolic viral sensor
MDA-5), or Pam3CSK4 (PAM; TLR2 agonist) (Amit et al., 2009).
These three TLRs activate transcriptional programs referred
to here as ‘‘inflammatory’’ (TLR2), ‘‘antiviral’’ (TLR3), or both
(TLR4) (Figure 1A) (Amit et al., 2009; Doyle et al., 2002).
Our analysis uncovered 280 genes annotated as known or
putative signaling molecules that were differentially expressed
followingstimulation:115kinases,69phosphatases,and96other
regulators, such as adaptors and scaffolds (Figure 1B, Table S1,
and Experimental Procedures). These 280 genes were enriched
for canonical pathways of the TLR network such as MAP kinase
(p < 1.22 3 1015, overlap 25/87, hypergeometric test), TLR
(e.g., Myd88, Traf6, Irak4, Tbk1; p < 8.43 3 1012, 21/86), and
PI3K (p < 2.58 3 108, 11/33) pathways, as well as the PYK2
pathway (p< 3.123 1010, 12/29),whichwas recently associated
with the TLR system (Wang et al., 2010). Overall, 94 of the 280
genes (33%) were associated with the TLR network in the litera-
ture (Table S1), supporting the validity of our candidate selection
strategy. The remaining 186 genes (67%) represent candidate
TLR components. To test their putative function in TLR signaling,
we selected a subset of 23 candidates based on their strong
differential expression and to proportionally represent the five
main induced expression clusters (Figures 1B and 1C). We also
selected six canonical TLR components (Myd88, Mapk9, Tbk1,
Ikbke, Tank, andMap3k7) as benchmarks (Figures 1A and 1D).
A Perturbation Strategy Places Uncharacterized
Signaling Components within the Antiviral and
Inflammatory Pathways
We perturbed our 6 positive controls and 17 of the 23 candidates
in BMDCs using shRNA-encoding lentiviruses (6 candidates
showed poor knockdown efficiency) (Table S1). We stimulated
the cells with LPS and used a multiplex mRNA counting method
to measure the effect of gene silencing on the mRNA levels of
118TLR responsesignaturegenes, representing the inflammatory
and antiviral programs (Figure 2A). Notably, the expression of the
118 genes was not affected in BMDCs transduced with lentivirus
compared to untransduced cells (Amit et al., 2009). We deter-
mined statistically significant changes in the expression of signa-
ture transcripts upon individual knockdowns based on compar-
ison to 10 control genes, whose expression remains unchanged854 Cell 147, 853–867, November 11, 2011 ª2011 Elsevier Inc.upon TLR activation, and to control shRNAs (Experimental
Procedures). Finally, we associated signaling molecules and
downstream transcriptional regulators that may act in the same
pathway by comparing the perturbational profiles of the 23
signalingmolecules (6 canonical and 17 candidates) to each other
and to those of the 123 transcriptional regulators (including tran-
scription and chromatin factors and RNA-binding proteins) previ-
ously tested (Figures 2 and S2 and Table S2) (Amit et al., 2009).
Perturbing 5 of the 6 canonical signaling molecules strongly
affected the expression of TLR signature genes, consistent
with their known roles (Figure 2A and Table S2) and validating
our approach. For example, perturbing Myd88, a known inflam-
matory adaptor, specifically abrogated the transcription of
inflammatory genes (e.g.,Cxcl1, Il1a, Il1b, Ptgs2, Tnf; Figure 2A),
similar to perturbations of downstream inflammatory transcrip-
tion factors (e.g., Nfkb1, Nfkbiz; Figure 2B). In addition, Tank
acted as a negative regulator of a subset of antiviral genes (Fig-
ure 2A), as expected (Kawagoe et al., 2009), and Tbk1 knock-
down affected both antiviral and inflammatory outputs (Fig-
ure 2A), consistent with findings that Tbk1 regulates NF-kB
complexes (Barbie et al., 2009; Chien et al., 2006). Notably, Ikbke
(IKK-ε) knockdown did not affect our gene signature, consistent
with previous observations that IKK-ε/ DCs respond normally
to LPS and viral challenges (Matsui et al., 2006). Thus, IKK-εmay
be either not functional or redundant in our system.
All of the 17 candidate signaling molecules tested, except Plk2
(discussed below), affected at least 6 of the 118 genes (on
average, 16.6 targets ± 10.4 standard deviation [SD]), and 12
affected more than 10% of the genes (Figures S2A and S2D).
Notably, perturbations of these 17 candidates did not affect
BMDC differentiation (88.3% ± 6.8% SD of CD11c+ cells;
Table S1). These effects are comparable to those of known
signaling molecules and transcriptional regulators in this system
(Figures S2B–S2E). For example, the receptor tyrosine kinase
Met, not previously associated with TLR signaling, affected
a number of signature genes similar to Tbk1 (Figures S2C
and S2D), in both the inflammatory and antiviral programs
(Figure 2A). Conversely, both the phosphatase Ptpre and the
adaptor Socs6 positively regulated the inflammatory program,
although negatively regulating some antiviral genes (Figure 2B).
Of the 17 candidates tested when we originally conducted this
screen, 10 have subsequently been reported in other studies
as functional in the TLR system (Table S1), providing an inde-
pendent confirmation. For example, here Map3k8 knockdown
affected both inflammatory and antiviral target genes (Figure 2A),
consistent with its reported role in the TLR pathways based on
Sluggish mice (Xiao et al., 2009).
We identified both primary (e.g., Myd88) and secondary
(e.g., Stat1) mediators of TLR responses. Although secondary
mediators are not part of the initial intracellular signaling
cascade, they are important physiological components of the
TLR response, and their pertubation can lead to phenotypic
outcomes similar to those of primary components. For example,
the receptor tyrosine kinase Mertk acted as both a positive and
negative regulator of some inflammatory and antiviral genes
(e.g., Ifnb1), respectively (Figure 2A), consistent with its reported
role as a secondary inhibitor of the TLR pathways (Rothlin et al.,
2007).
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Figure 1. mRNAs of Signaling Components Are Differentially Regulated upon TLR Stimulation
(A) Simplified schematic of the TLR2, 3, and 4 pathways (Takeuchi and Akira, 2010).
(B) mRNA expression profiles of differentially expressed signaling genes. Shown are expression profiles for 280 differentially expressed signaling genes (rows)
at different time points (columns): a control time course (no stimulation, Ctrl) and following stimulations with Pam3CSK4 (PAM), LPS, and poly(I:C). Tick marks:
time point poststimulation (0.5, 1, 2, 4, 6, 8, 12, 16, 24 hr). Shown are genes with at least a 1.7-fold change in expression compared to prestimulation levels in both
duplicates of at least one time point. The three leftmost columns indicate kinase (KIN), phosphatase (PSP), and signaling regulators (SIG) (black bars). Values from
duplicate arrays were collapsed and gene-expression profiles were hierarchically clustered. The rightmost color-coded column indicates the five major
expression clusters.
(C and D) mRNA expression profiles of candidate (C) and canonical (D) TLR signaling regulators selected for subsequent experiments. The color-coding of the
gene names highlights the corresponding expression clusters from the complete matrix from (A).
See also Figure S1 and Table S1.
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Figure 2. A Perturbation Strategy Assigns Function to Signaling Components within the TLR Pathways
(A) Perturbation profiles of 6 canonical (purple) and 17 candidate (blue) signaling components and 20 core TLR transcriptional regulators belonging to the
inflammatory (orange) and the antiviral (green) programs. Shown are the perturbed regulators (columns) and their statistically significant effects (FDR < 0.02) on
each of the 118 TLR signature genes (rows). Red: significant activating relation (target gene expression decreased following perturbation); blue: significant
repressing relation (target gene expression increased following perturbation); white: no significant effect. The rightmost column categorizes signature genes into
antiviral (light gray) and inflammatory (dark gray) programs.
(B) Functional characterization based on similarity of perturbation profiles. Shown is a correlation (Pearson) matrix of the perturbation profiles from (A). Yellow:
positive correlation; purple: negative correlation; black: no correlation.
See also Figure S2 and Table S2.Crkl Modulates JNK-Mediated Antiviral Signaling
in the TLR Network
Among the 17 candidate signaling proteins, perturbation of the
tyrosine kinase adaptor Crkl decreased expression of 13% of
the signature genes, especially antiviral ones (Figures 2A and
S2D). Crkl belongs to several signaling pathways, including early
lymphocyte activation (Birge et al., 2009), but has not been asso-
ciated with the TLR network. Crkl’s perturbation profile closely
resembled those of known antiviral regulators, most notably
Jnk2 (Mapk9; Chu et al., 1999) (Figures 2A and 3A). Indeed,
when Crkl/ DCs were stimulated with LPS, the expression of856 Cell 147, 853–867, November 11, 2011 ª2011 Elsevier Inc.antiviral cytokines (Cxcl10, Ifnb1) was strongly reduced (Fig-
ure 3B, left and middle), but that of an inflammatory cytokine
(Cxcl1) was unaffected (Figure 3B, right).
To test whether Crkl is a primary component of the TLR
pathway, we determined whether Crkl phosphorylation is rapidly
modified after TLR signaling initiation. Using SILAC-based (Ong
et al., 2002) quantitative phosphoproteomics, we identified and
quantified 62 phosphotyrosine (pTyr)-containing peptides from
BMDCs stimulated with LPS for 30 min (Figure 3C, Table S3,
and Experimental Procedures). Of these 62 phosphopeptides,
7 and 9 were significantly up- or downregulated, respectively
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Figure 3. Crkl Adaptor Functions in the Antiviral Arm of TLR4 Signaling
(A) Comparison of Crkl and Mapk9 knockdown profiles. Shown are the effects of Crkl and Mapk9 perturbation (columns) on the 118 signature genes (rows).
Data were extracted from Figure 2A.
(B) Inhibition of transcription of antiviral cytokines in Crkl/ BMDCs. Shown are mRNA levels (qPCR; relative to t = 0) for Ifnb1 (left), Cxcl10 (middle), and Cxcl1
(right) in three replicates per time point. Error bars represent the standard error of the mean (SEM) (n = 3 mice).
(C) Crkl phosphorylation is induced following LPS stimulation. Top: schematic depiction of experimental workflow. From left: Protein lysates from unstimulated
(control) and LPS-treated BMDCs grown in ‘‘light’’ and ‘‘heavy’’ SILAC medium were mixed (1:1) and digested into peptides with trypsin before phosphotyrosine
(pY) peptide enrichment by immunoprecipitation and LC-MS/MS analysis. Bottom: Shown are the differential phosphorylation levels (log 2 ratios, y axis) of all
62 phosphopeptides identified and quantified by LC-MS/MS (x axis). Black: peptides with more than 2-fold differential expression (left: induced; right: repressed).
See also Table S3.
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Figure 4. Plk2 and 4 Regulate the Antiviral Program
(A) Similarity ofPlk2 and 4mRNAexpression profiles. Shown aremRNA levels (from Figure 1B) ofPlk2 (left) andPlk4 (right) following stimulation with LPS (black) or
poly(I:C) (gray). Error bars represent the SEM.
(B) Double knockdown ofPlk2 and 4 represses the antiviral signature. Shown are significant changes in expression of TLR signature genes (rows) following double
knockdown of Plk2 and 4. Red and blue mark significant hits as in Figure 2, only for genes where the effect was consistent between the two independent
combinations of shRNAs.
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(Figure 3C and Table S3). A phosphopeptide derived from Crkl
(Y132)—one of the top 6 induced phosphopeptides—was
induced 2.1-fold (Figure 3C). This indicates that Crkl is likely acti-
vated directly downstream of TLR4 signaling.
Several lines of evidence suggest that Crkl acts through Jnk2
(Mapk9) signaling. First, the MAP kinase Jnk2 (Mapk9) is coregu-
lated at the phosphorylation level with Crkl upon LPS stimulation
(Figure 3C). Second, the Crk adaptor family—including CrkI,
CrkII, and Crkl—has been shown to modulate Jnk activity in
growth factor and IFN signaling (Birge et al., 2009; Hrincius
et al., 2010). Third, the perturbation profiles of Mapk9 and Crkl
are strikingly similar (Figure 3A). These observations suggest
that Crkl modulates Jnk-mediated antiviral signaling in the
TLR4 pathway, providing a possible explanation for why the
NS1 protein of influenza A virus may target Crkl (Heikkinen
et al., 2008; Hrincius et al., 2010).
Polo-like Kinases Are Critical Activators of the Antiviral
Program
To discover potential drug targets among our 17 candidates, we
next focused on Plk2, a well-known cell-cycle regulator and drug
target (Strebhardt, 2010). The roles of Plks in nondividing, differ-
entiated cells are poorly defined (Archambault and Glover, 2009;
Strebhardt, 2010).We have previously shown that transcriptional
regulators of cell-cycle processes (e.g., Rbl1, Rb, Myc, Jun,
E2fs) are co-opted to function in the antiviral responses in DCs
(Amit et al., 2009). However, neither knockdown (Figure 2A) nor
knockout (Figure S3A) of Plk2 in BMDCs had any effect on the
TLR response. We hypothesized that this could be due to func-
tional redundancy with another Plk, as Plk4 mRNA was induced
in DCs similarly to Plk2 (Figure 4A), albeit at a lower amplitude
(and thus was below our threshold for inclusion in the initial
candidate list). Interestingly, functional redundancy between
Plk2 and 4 has been suggested to account for the viability of
Plk2-deficient mice (Strebhardt, 2010), and Plk2 and 4 have
been reported to function together in centriole duplication
(Chang et al., 2010; Cizmecioglu et al., 2008).
To test our hypothesis, we simultaneously perturbed Plk2 and
4 in BMDCs using two independent mixes of different pairs of
shPlk2/shPlk4 (Figure S3B and Experimental Procedures). We
observed a significant and specific decrease in the expression
of 21 antiviral genes (Figure 4B). For example, the antiviral cyto-
kines Ifnb1 and Cxcl10 mRNAs were decreased, whereas the
expression of the inflammatory geneCxcl1 and almost all inflam-
matory signature genes remained unaffected (Figure 4C). Two
recent reports suggested a role for Plk1 alone as a negative regu-
lator of MAVS (Vitour et al., 2009) and NF-kB (Zhang et al., 2010)
in cell lines. However, knockdown of either Plk1 or 3 in BMDCs
did not affect the TLR transcriptional response (Figure S3C
and Table S2). Notably, BMDC viability was unaffected by lenti-(C) Double knockdown of Plk2 and 4 represses antiviral cytokine mRNAs. Shown a
cytokines (Ifnb1 and Cxcl10) and for an inflammatory cytokine (Cxcl1), following
(Plk2/4-1, Plk2/4-2). Three replicates for each experiment; error bars are the SEM
(D and E) BI 2536 specifically abrogates transcription of antiviral genes witho
Pam3CSK4. Shown aremRNA levels (qPCR; relative to t = 0) for 12 indicated antivi
color bars) or DMSO vehicle (light color bars) and stimulated for 0, 2, or 4 hr with
See also Figures S3 and S4 and Table S4.viral shRNA transduction targeting Plk1, 2, 3, or 4 individually or
Plk2 and 4 together (based on mRNA levels of control genes;
Table S2). Thus, in BMDCs, Plk2 and 4, but likely not Plk1 or 3,
are critical regulators of antiviral but not cell-cycle pathways.
A Small-Molecule Inhibitor of Plks Represses Antiviral
Gene Expression and IRF3 Translocation in DCs
We next targeted Plks in BMDCs using BI 2536, a commercial
pan-specific Plk small-molecule inhibitor (Steegmaier et al.,
2007). We compared genome-wide mRNA profiles from BMDCs
treated with either BI 2536 or DMSO vehicle before stimulation
with LPS or poly(I:C) (Experimental Procedures). BI 2536 treat-
ment repressed mostly antiviral gene expression compared to
DMSO (99/193 genes in response to poly(I:C), p < 1 3 1071,
hypergeometric test; 67/194 in response to LPS; Table S4).
The 311 unique LPS- and/or poly(I:C)-induced genes that are
repressed by BI 2536 are significantly enriched for genes related
to cytokine signaling (e.g., IL-10, type I IFNs, IL-1), TLR signaling,
and DC signaling and for gene ontology (GO) processes related
to defense and immune responses (Figure S4A). Consistent with
the array data, BI 2536 strongly inhibited the expression of 12
well-studied antiviral genes, whereas inflammatory gene expres-
sion remained largely unaffected in DCs stimulated with LPS,
poly(I:C), or Pam3CSK4, as measured by qPCR (Figure 4D).
BI 2536 reduced the mRNA levels of Cxcl10 and Ifnb1 (by
qPCR) and of secreted IFN-b in a dose-dependent manner,
whereasCxcl1 expression was not significantly affected (Figures
S4B and S4C). Importantly, BI 2536 treatment prestimulation
impacted neither the viability nor the cell-cycle state of BMDCs
(Figures S4D and S4E), suggesting that Plk inhibition does not
act through cell-cycle effects. Consistent with our shRNA and
BI 2536 perturbations, two other pan-Plk inhibitors—structurally
unrelated to BI 2536—also repressed Ifnb1 and Cxcl10 expres-
sion without affecting Cxcl1 (Figure S4F). This strongly suggests
that the effects induced by these perturbations are due to
Plk inhibition and not off-target effects. Furthermore, we
observed a similar inhibitory effect of BI 2536 on Ifnb1 induction
in Ifnar1/ and wild-type BMDCs, demonstrating that Plks
act directly downstream of TLR activation and not in an auto-
crine/paracrine feedback loop mediated by IFN receptor
signaling (Figure S4G). This is consistent with a recent phospho-
proteomic study reporting an enrichment for Plk substrates as
early as 15 min after LPS stimulation in macrophages (Weintz
et al., 2010).
We next used confocal microscopy to monitor the effect of BI
2536 on the subcellular localization of IRF3, a key antiviral tran-
scription factor. To more effectively deliver the drug, we plated
BMDCs on vertical silicon nanowires (Shalek et al., 2010) pre-
coated with BI 2536 prestimulation. Nanowires alone had no
effect on the TLR response (Figures 5A and S5A). BI 2536re expression levels (qPCR) relative to control shRNAs (control) for two antiviral
LPS stimulation in BMDCs using two independent combinations of shRNAs
.
ut affecting inflammatory genes following stimulation with LPS, poly(I:C), or
ral (D) and 12 inflammatory (E) genes in BMDCs treatedwith BI 2536 (1 mM; dark
LPS (dark and light). Error bars represent the SEM.
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Figure 5. BI 2536-Mediated Plk Inhibition Blocks IRF3 Nuclear Translocation in DCs
(A) DCs on NW undergo normal morphological changes upon LPS stimulation. Shown are electron micrographs of BMDCs plated on bare vertical silicon NW that
were left unstimulated (left; control) or stimulated with LPS (right). Scale bars, 5 mm.
(B–E) BI 2536 inhibits IRF3, but not NF-kB p65, nuclear translocation following TLR stimulation. (B and D) Shown are confocal micrographs of BMDCs plated on
vertical silicon NW precoated with vehicle control (DMSO; B and D), Plk inhibitor (BI 2536; B and D), or control Jnk inhibitor (SP 600125; B) and stimulated with
poly(I:C) for 2 hr (B) or LPS for 30 min (D) (reflecting peak time of nuclear translocation for IRF3 and NF-kB p65, respectively) or left unstimulated (B and D). Cells
were analyzed for DAPI (B and D), IRF3 (B), and NF-kB p65 subunit (D) staining. Scale bars, 5 mM. (C and E) Nuclear translocation (from confocal micrographs) of
IRF3 (C) and NF-kB p65 (E) was quantified using DAPI staining as a nuclear mask (purple circles; overlay in B and D) to determine the ratio of total versus nuclear
fluorescence (y axis) in BMDCs cultured on NW coated with different amounts of BI 2536 or SP 600125 or with vehicle control (DMSO; x axis). Three replicates in
each experiment; error bars are the SEM.
See also Figure S5.inhibited IRF3 nuclear translocation in a dose-dependent
manner upon poly(I:C) or LPS stimulation, whereas the control
JNK inhibitor SP 600125 had no effect (Figures 5B, 5C, and
S5B). On the other hand, BI 2536 did not affect NF-kB p65 local-860 Cell 147, 853–867, November 11, 2011 ª2011 Elsevier Inc.ization (Figures 5D and 5E). Notably, IRF3 translocation was also
decreased when delivering BI 2536 in solution, but to a lesser
extent compared to nanowire-mediated delivery (Figure S5C),
highlighting the utility of highly efficient drug delivery methods
to induce homogeneous effects in single-cell assays. Altogether,
these results place Plk2 and 4 as critical regulators of the antiviral
program, upstream of a major antiviral transcription factor.
Plks Are Essential for Activation of All Well-Established
IFN-Inducing Pathways in Conventional and
Plasmacytoid DCs
DCs can be broadly categorized into two major subtypes—
conventional and plasmacytoid DCs—each relying on distinct
mechanisms to induce type I IFNs and antiviral gene expression
(Blasius and Beutler, 2010). In conventional DCs (cDCs), antiviral
responses are activated through TLR4/3 signaling (via TRIF) or
through the cytosolic sensors RIG-I or MDA-5 (via MAVS) (Fig-
ure 6A). In plasmacytoid DCs (pDCs; specialized IFN-producing
cells), the antiviral response depends solely on endosomal TLR7
and 9 that signal via MYD88 (Figure 6A) (Blasius and Beutler,
2010; Takeuchi and Akira, 2010).
BI 2536 treatment showed that Plks are essential for the viral-
sensing pathways in both cDCs and pDCs. In cDCs, BI 2536
inhibited the transcription of antiviral genes (Ifnb1 and Cxcl10)
upon infection with each of four viruses: vesicular stomatitis virus
(VSV; Figure 6B, top), Sendai virus (SeV; Figure S6A, top), New-
castle disease virus (NDV; Figure S6A, bottom) (all three sensed
through RIG-I), and encephalomyocarditis virus (EMCV), sensed
through MDA-5 (Figure 6B, bottom and Experimental Proce-
dures). Notably, BI 2536 neither affected the mRNA level of
Cxcl1 (an inflammatory cytokine) in any of the four cases nor
affected the response to heat-killed Listeria monocytogenes,
a natural TLR2 agonist (Figures 6B, S6A, and S6B). In pDCs, BI
2536 treatment nearly abrogated the transcription of mRNAs
for the antiviral cytokines Ifnb1, Ifna2, and Cxcl10 after stimula-
tion with type A CpG oligonucleotides (CpG-A) or infection with
EMCV, sensed by TLR9 and 7, respectively (Figures 6C and
S6C and Experimental Procedures). Conversely, in pDCs stimu-
lated with CpG-B—a ligand known to activate inflammatory
pathways but not IFN-inducing pathways—BI 2536 treatment
decreased Cxcl10 mRNA, while moderately increasing Cxcl1
mRNA (Figure 6C). Finally, of our 118 signature genes, BI 2536
repressed genes induced by CpG-A alone or by both CpG-A
and -B, although having aminor effect, if any, on CpG-B-specific
genes in pDCs (Figure 6D and Table S5). These findingsmay help
reveal the poorly characterized molecular determinants of IFN
production in pDCs (Reizis et al., 2011) and demonstrate a critical
role for Plks across all well-known IFN-inducing pathways.
Plks Are Essential in the Control of Host Antiviral
Responses
To assess the impact of Plk inhibition on the outcome of viral
infection, we infected primary mouse lung fibroblasts (MLFs)
with influenza virus. BI 2536-treated MLFs infected with influ-
enza failed to produce interferon (Figure 6E) and showed
elevated replication of both wild-type (PR8) and poorly repli-
cating mutant (DNS1) viruses (Figure 6F). The reduced interferon
response was not due to drug-induced toxicity (Figure 6G).
Next, we tested the effects of Plk inhibition in virally infected
mice. BI 2536 exhibits good tolerability in mice (Steegmaier
et al., 2007) and humans (Mross et al., 2008) and is currently in
phase II clinical trials as an antitumor agent in several cancers(Strebhardt, 2010). Given its efficacy and safety in vivo, we tested
whether BI 2536 would also affect the response to viral infection
in animals. In mice infected with VSV, BI 2536 strongly sup-
pressed mRNA production in popliteal lymph nodes for type I
IFNs (Ifnb1, Ifna2) and Cxcl10 but did not affect Cxcl1 mRNA
induction (all compared to vehicle control; Figures 6H and
S6D). Concomitantly, VSV replication in the lymph node rapidly
increased as reflected by elevated VSV RNA levels (Figure 6I),
comparable to the observed phenotype of VSV-infected
Ifnar1/mice (Iannaconeet al., 2010). Because in theVSVmodel
used here type I IFNs are produced by both infected CD169+
subcapsular sinus macrophages and pDCs (Iannacone et al.,
2010), we cannot distinguish whether Plk inhibition affects
macrophages, pDCs, or both. Nevertheless, our results confirm
thephysiological importance of Plks in the host antiviral response
in both ex vivo primary MLFs and in vivo mouse lymph nodes.
Plks Affect the Phosphorylation of Dozens of Proteins
Post-LPS Stimulation, including Known and Candidate
Antiviral Regulators
Wenext sought to discover the signaling pathways between Plks
and antiviral gene transcription. We used microwestern arrays
(MWAs) (Ciaccio et al., 2010) to measure changes in the phos-
phorylation and protein levels of 20 and 6 TLR pathway proteins,
respectively, in BMDCs at each of 12 combinations of four time
points (0, 20, 40, 80 min after LPS stimulation) and three pertur-
bations (vehicle control, BI 2536, and negative control JNK inhib-
itor SP 600125) (Table S6). Although LPS stimulation alone led to
the expected changes (e.g., early peak of phosphorylation for
ERK1/2, p38, andMapkapk2 and rapid degradation of IkBa; Fig-
ure 7A), BI 2536 surprisingly did not cause any significant
changes (Figures 7A, S7A, and S7B). We therefore hypothesized
that Plks could affect previously unrecognized regulators of IFN-
inducing pathways and/or known regulators with no existing
antibodies to specific phosphosites.
Next, we used SILAC-based unbiased phosphoproteomics
(Figure 7B, top) (Ville´n and Gygi, 2008) to compare the levels
of phosphotyrosine, -threonine, and -serine peptides following
stimulation with LPS (for 30 or 120 min) in BMDCs pretreated
with BI 2536 versus those treated with vehicle (DMSO). We iden-
tified and quantified 5,061 and 5,997 phosphopeptides after
30 and 120 min, respectively, for a total of 10,236 individual
phosphosites (Figure 7B and Table S6). BI 2536 substantially
affected the TLR phosphoproteome, leading to a significant
(p < 0.001) change in the level of 510 phosphopeptides derived
from 413 distinct proteins (Figure 7B and Table S6). Further sup-
porting our results, 35% (2489/7018) of the phosphosites we
identified were recently reported in mouse bonemarrow-derived
macrophages treated with LPS (Figure S7C, left) (Weintz et al.,
2010), and 483 of our phosphosites were among 1,858 sites
(26%) reported in a phosphoproteomic study of LPS signaling
in a macrophage cell line (Figure S7C, left) (Sharma et al.,
2010). A comparison of the phosphosites of known kinases
showed similar overlaps between the three studies (Figure S7C,
right).
The Plk-dependent phosphoproteins include several known
regulators of antiviral pathways (e.g., Prdm1, Fos, Unc13d) (Cro-
zat et al., 2007; Keller and Maniatis, 1991; Takayanagi et al.,Cell 147, 853–867, November 11, 2011 ª2011 Elsevier Inc. 861
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Figure 6. Plks Are Critical in the Induction of Type I Interferons In Vitro and In Vivo
(A) IFN-inducing pathways in cDCs and pDCs.
(B and C) BI 2536 inhibits mRNA levels for antiviral cytokines in response to diverse stimuli in cDCs and pDCs. Shown are Ifnb1, Cxcl10, and Cxcl1 mRNA
levels (qPCR; relative to t = 0) in cells treated with BI 2536 (1 mM; white bars) or DMSO vehicle (black bars) in cDCs (B) infected with VSV (multiplicity of infection
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2002), as well as many additional protein candidates with no
previously known function in viral sensing (Figure 7B and Table
S6). Notably, proteins involved in the TBK1/IKK-ε/IRF3 axis
were detected and quantified, but their phosphorylation levels
were unchanged upon Plk inhibiton (Table S6), consistent
with the MWA data. Conversely, Plk inhibition with BI 2536
decreased the phosphorylation levels of cell-cycle regulators
of the Jun family of transcriptional regulators (i.e., Jund) that
we previously found to be co-opted by antiviral pathways
(Amit et al., 2009). BI 2536 treatment also decreased the phos-
phorylation levels of the mitotic kinases Nek6 and Nek7 (Fig-
ure 7B). The recent observation that the phosphorylation of
Nek6 substrates is increased following LPS stimulation inmacro-
phages (Weintz et al., 2010) indirectly corroborates our finding
that Nek6may be active in TLR signaling. To test the role of these
Plk-dependent candidates, we returned to our shRNA perturba-
tion-based approach.
Plk-Dependent Phosphoproteins Affect
the Antiviral Response
We perturbed 25 Plk-dependent phosphoproteins (Table S7),
using shRNA perturbation in BMDCs followed by qPCR and TLR
gene signature measurements. These candidates satisfied three
criteria: (1) there was no prior knowledge of their function in
viral-sensing pathways; (2) their phosphoprotein levels were con-
sistently up- or downregulated upon BI 2536 treatment (in two
independent experiments); and (3) they had detectable mRNA
expression and/or differential expression upon stimulation.
Of the 18 phosphoproteins showing efficient knockdown, 11
caused a significant decrease in Ifnb1 mRNA levels with a single
shRNA (Sash1, Dock8, Nek6, Nek7, Nfatc2, and Ankrd17; Fig-
ure S7D) or with two independent shRNAs (Tnfaip2, Samsn1,
Arhgap21, Mark2, and Zc3h14; Figure S7E). Decrease in
Cxcl10 expression was less prominent, consistent with our
previous observations of BI 2536’s weaker effect on this cytokine
during LPS stimulation (Figures S7D and S7E, far right panels).
Each of the 11 Plk-dependent phosphoproteins tested affected
at least 9 targets in the 118-gene signature (on average, 39
targets ± 30 SD; Figure 7C), and 9 affected more than 10% of
the targets in the TLR gene signature (Figure 7C).
Nine of the 11 Plk-dependent phosphoproteins affected the
TLR signature comparably to major antiviral regulators (Fig-
ure 7D). For example, the knockdown profiles of Samsn1,
Dock8, and Sash1 were closely correlated to those of Stat and
Irf family members (Figure 7D), and those of Tnfaip2 and[moi] 1; B, top) or with EMCV (moi 10; B, bottom) and in pDCs (C) stimulated w
experiment; error bars are the SEM.
(D) BI 2536 inhibits the CpG-A response but has little effect on the CpG-B respons
pDCs treated with DMSO vehicle or BI 2536 (1 mM) and left untreated (Ctrl) or stim
CpG-A-specific (top), CpG-B-specific (bottom), and shared by CpG-A and -B (m
(E–G) BI 2536 inhibits IFN-b production in primary MLFs, leading to an increase in
(DMSO; black bars) were infectedwith influenzaDNS1 or PR8 strains at indicated
replication as measured by luciferase (Luc) activity in reporter cells (F), and cell v
(H and I) BI 2536 inhibits antiviral cytokine mRNA production, while increasing vir
mRNA (H) and VSV viral RNA (I) levels (qPCR; relative to uninfected animals) from
vehicle (black circles) prior to and during the course of infection with VSV (intra-fo
animal (n = 3). Data are representative of three independent experiments for eac
See also Figure S6 and Table S5.Zc3h14 were most correlated to the Plk2/4 double knockdown.
Interestingly, Tnfaip2, a protein of unknown molecular function,
has been associated with rheumatoid arthritis and autoimmune
myocarditis in genome-wide association studies (Wellcome
Trust Case Control Consortium, 2007; Kuan et al., 1999). Our
findings provide a potential molecular context for this disease
association.
DISCUSSION
Using an integrative strategy combining transcriptomics,
genetic and chemical perturbations, and unbiased phosphopro-
teomics, we established a role for Plks in host defense pathways
inducing type I IFNs, likely by controlling the phosphorylation
and activity of a module of at least 11 components (Figure 7E).
Our findings and approach open up several avenues for future
investigations.
Consistent with our finding that cell-cycle transcription factors
play a role in antiviral responses (Amit et al., 2009), we identified
several cell-cycle kinases (Plks, Neks) as important regulators
of these responses. Despite extensive studies on the role of
Plk1 in mitosis, the functions of its paralogs—Plk2, 3, and 4—
are poorly defined (Strebhardt, 2010). Although they are less
essential than Plk1 in regulating cell division, their roles in nondi-
viding cells such as neurons are emerging (Archambault and
Glover, 2009; Seeburg et al., 2005). Interestingly, silencing of
both Plk2 and 4 was required to reveal their importance in
antiviral responses, highlighting the necessity of epistasis
analysis in studying mammalian signaling networks. Although it
is currently not feasible to screen for genetic interactions at
a genome-wide scale, it will be interesting to develop innovative
approaches to uncover them.
BI 2536 blocked the nuclear translocation of IRF3 without
affecting its phosphorylation level (based on MWAs and phos-
phoproteomics). A similar phenomenon has been reported for
NF-kB (Ye et al., 2011). This suggests that IRF3 translocation
in our system is likely to be regulated by a mechanism that
does not impact phosphorylation.
Furthermore, Plk inhibition suppresses type I IFN production
in vivo during viral infection—a finding that has potential clinical
implications. Indeed, disease activity in patients with Systemic
Lupus Erythematosus (SLE) correlates with IFN expression
signatures (Banchereau and Pascual, 2006), and lupus-prone
mice exhibit reduced symptoms upon treatment with a dual
inhibitor of TLR7 and 9 (Barrat and Coffman, 2008) or deletionith CpG type A or B or infected with EMCV (moi 10). Three replicates in each
e. Shown are mRNA levels (nCounter) for the 118 TLR signature genes (rows) in
ulated with CpG-A or -B for 6 hr (columns). Three clusters of genes are shown:
iddle).
viral replication. MLFs treated with BI 2536 (1 mM; white bars) or vehicle control
mois. Shown are Ifnb1mRNA levels measured by qPCR (relative to t = 0; E), viral
iability measured by CellTiter-Glo assay (G). Error bars represent the SEM.
al replication during in vivo VSV infection. Shown are Ifnb1, Cxcl10, and Cxcl1
popliteal lymph nodes of mice injected with BI 2536 (white circles) or DMSO
otpad). Nodes were harvested 6 hr post-infection. Each circle represents one
h condition.
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Figure 7. Unbiased Phosphoproteomics Identifies a Plk-Dependent Antiviral Pathway
(A) BI 2536 does not affect phosphorylation and protein levels of known TLR signaling nodes. Shown are representative MWA (see Experimental Procedures)
blots (left) obtained from analyzing lysates from BMDCs pretreated with DMSO, BI 2536 (1 mM), or SP 600125 (5 mM) and stimulated with LPS for 0, 20, 40, and
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of the IFN receptor (Santiago-Raber et al., 2003). Thus, testing
the effect of BI 2536 on a mouse model of lupus will be key to
assess the potential therapeutic implications of Plk inhibition
for SLE.
Our approach may be applicable for characterizing the func-
tions of genes reported in genome-wide association studies
(e.g., Tnfaip2), for uncovering potential therapeutic targets
(e.g., Plks), and for repurposing existing small molecules in
new physiological contexts (e.g., using the cancer drug BI
2536 to repress innate immune responses). The vast public
compendia of microarray data could serve as starting points
for identification of relevant signaling components in diverse
biological systems, followed by perturbations and signature
measurements. Nevertheless, because the mRNAs correspond-
ing to many pathway components do not change upon pathway
activation, our approach is far from exhaustive. Combination of
our perturbation-based approach with large-scale biochemical
measurements (e.g., posttranslational modifications, protein-
protein interactions) will lead to more comprehensive, integrated
maps of signaling and transcriptional networks.
EXPERIMENTAL PROCEDURES
Cells and Mouse Strains
BMDCs were generated from 6- to 8-week-old female C57BL/6J mice, Crkl
mutant mice (Jackson Laboratories), Plk2/ mice (Elan Pharmaceuticals),
or Ifnar1/ mice (gift from K. Fitzgerald). Primary MLFs were from C57BL/
6J mice.
Viruses
SeV strain Cantell and EMCV strain EMC (ATCC), NDV strain Hitchner B1 (gift
from A. Garcia-Sastre), and VSV strain Indiana (U. von Andrian) were used for
infections. Influenza A virus strain A/PR/8/34 and DNS1 were grown in Vero
cells, and virus titers from MLF supernatants were quantified using 293T cells
transfected with a vRNA luciferase reporter plasmid.
Reagents
TLR ligands were from Invivogen (Pam3CSK4, ultra-pure E. coliK12 LPS, ODN
1585 CpG type A, and ODN 1668 CpG type B) and Enzo Life Sciences
(poly(I:C)). Heat-killed Listeria monocytogenes (HKLM) was from Invivogen.
Polo-like kinase inhibitors were from Selleck (BI 2536), Sigma (GW843682X),
and Chembridge (Poloxipan). SP 600125 (Jnk inhibitor) was from Enzo Life
Sciences.80min. Blots were analyzed using indicated antibodies (leftmost), and fold change
SEM of triplicate MWA blots.
(B) BI 2536 affects protein phosphorylation levels during LPS stimulation. Top: Sc
BMDCs cultured in ‘‘heavy’’ or ‘‘light’’ SILAC medium were pretreated with BI 253
into peptides with trypsin, before phosphoserine, -threonine, and -tyrosine (pS
differential phosphorylation levels (average log2 ratios of two independent experi
and quantified by LC-MS/MS (x axis) at 30 min (top) and 120 min (bottom) p
(Punadjusted < 0.001 for both time points; FDR30min = 0.05; FDR120min = 0.03; left: in
quantified in two independent experiments are depicted.
(C) Eleven Plk-dependent phosphoproteins significantly affect the expression of
signature genes (rows) following knockdown of each of the 11 phosphoproteins (c
hits (as presented in Figure 2) and are shown only for genes where the effect wa
(D) Functional characterization based on similarity of perturbation profiles. Shown
those from Figure 2B including canonical (purple) and candidate (blue) signaling
scriptional regulators. Yellow: positive correlation; purple: negative correlation; b
(E) A Plk-dependent pathway in antiviral sensing. Shown is a diagram of a model o
Plk-dependent proteins described in (C) and (D), only the 5 showing a phenotyp
See also Figure S7 and Tables S6 and S7.mRNA Isolation, qPCR, and Microarrays
Total or poly(A)+ RNA was extracted and reverse transcribed prior to qPCR
analysis with SYBR Green (Roche) in triplicate with GAPDH for normalization.
For microarray analysis, Affymetrix Mouse Genome 430A 2.0 Array was used.
shRNA Knockdowns
High-titer lentiviruses expressing shRNAs were obtained from The Broad RNAi
Platform and used to infect BMDCs as previously described (Amit et al., 2009).
mRNA Measurements on nCounter
53 104 BMDCswere lysed in RLT buffer (QIAGEN) with 1% b-ME. Ten percent
of the lysate was used for mRNA counting using the nCounter Digital Analyzer
(NanoString) and a previously generated CodeSet of 118 genes (Amit et al.,
2009). To score target genes whose expression is significantly affected by
shRNA perturbations, we used a fold threshold corresponding to a false
discovery rate (FDR) of 2%. Heatmaps and distance matrix analyses were
generated using the Gene-E software (http://www.broadinstitute.org/cancer/
software/GENE-E/).
Detection of Regulated Signaling Genes
We identified differentially regulated signaling components (i.e., kinases,
phosphatases, and signaling adaptors or scaffolds) based on probesets
reproducibly displaying at least 1.7-fold up- or downregulation in at least
one time point, compared to unstimulated controls, using our previously
published microarray dataset (NCBI GEO GSE17721, Amit et al., 2009).
Nanowire-Mediated Drug Delivery and Microscopy
BMDCs were plated on top of etched silicon nanowires (Si NWs) coated with
small molecules. After 24 hr, cells were stimulated and processed for immuno-
fluorescence analysis by confocal microscopy.
VSV Infection Model
Eight-week-old C57BL/6 male mice received 500 mg of BI 2536 (or vehicle)
intravenously and 50 mg into the footpad 3 hr before and 2 hr after infection
with 106 pfu of VSV into the footpad. Mice were sacrificed 6 hr post-infection,
and the draining popliteal lymph nodes were harvested in RNAlater solution
(Ambion) before subsequent RNA extraction and qPCR analysis.
Microwestern Arrays
The MWA method previously described (Ciaccio et al., 2010) was modified to
accommodate a larger number of lysates.
Phosphotyrosine and Global Phospopeptide Analysis
Tyrosine-phosphorylated peptides from BMDC lysates were prepared using
a PhosphoScan Kit (Cell Signaling Technology) and analyzed by data-depen-
dent LC-MS/MS using a Thermo LTQ-Orbitrap. Quantitative analysis ofin fluorescence signals was quantified relative to t = 0 (right). Error bars are the
hematic depiction of experimental workflow. From left to right: LPS-stimulated
6 (1 mM) or DMSO, respectively. Protein lysates were mixed (1:1) and digested
/T/Y) peptide enrichment and LC-MS/MS analysis. Bottom: Shown are the
ments; y axis) of all 5,061 and 5,997 phosphopeptides, respectively, identified
ost-LPS stimulation. Dark gray: phosphopeptides with a significant change
duced; right: repressed). Average ratios from phosphopeptides identified and
TLR signature genes. Shown are significant changes in expression of the TLR
olumns). Cells were stimulated with LPS for 6 hr. Red and blue mark significant
s consistent between two independent experiments.
is a correlation (Pearson) matrix of the perturbation profiles from (C) (gray) and
components as well as core antiviral (green) and inflammatory (orange) tran-
lack: no correlation.
f the Plk-dependent pathway of IFN induction in innate immunity. Out of the 11
e with two independent shRNAs are depicted.
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serine-, threonine-, and tyrosine-phosphorylated peptides was performed
using SCX/IMAC as described (Ville´n andGygi, 2008) with somemodifications.
Peptide samples were analyzed on a LTQ-Orbitrap Velos (Thermo Fisher
Scientific). To identify and quantify peptides, mass spectra were processed
with Spectrum Mill software package (Agilent Technologies) v4.0b, including
in-house developed features for SILAC quantitation and phosphosite localiza-
tion, and with MaxQuant (v1.0.13.13) (Cox and Mann, 2008) and Mascot
search engine (v2.2.0, Matrix Science).
ACCESSION NUMBERS
Complete microarray datasets are available in the NCBI Gene Expression
Omnibus (accession number GSE28520). Proteomics raw data are in the the
Tranche data repository (https://proteomecommons.org/tranche/, hash:
HTWY5ZeSLM1hyYEyfEiJREkgLXs6BZxCczuixy9XjULsync5HCkXx/8gB7n
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